Evidence map›Paper›PMID 40464407›Full record

ArticleInternational journal of cancer2025

The perioperative outcomes of retroperitoneal lymph node dissection in Germany for patients with testicular cancer: Results from the GRAND study.

Nikolaos Pyrgidis, Maria Apfelbeck, Marc Kidess, Philipp Weinhold, Julian Marcon, Gerald B Schulz, Yannic Volz, Benedikt Ebner, Peter Maximilian Sparwasser, Igor Tsaur and 3 more

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nikolaos PyrgidisDepartment of Urology, University Hospital LMU Munich, Munich, Germany.ORCID 0000-0002-7707-8426
Maria ApfelbeckDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Marc KidessDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Philipp WeinholdDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Julian MarconDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Gerald B SchulzDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Yannic VolzDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Benedikt EbnerDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Peter Maximilian SparwasserDepartment of Urology, University Hospital Tübingen, Tübingen, Germany.
Igor TsaurDepartment of Urology, University Hospital Tübingen, Tübingen, Germany.
Marcus HentrichDepartment of Hematology and Oncology, Red Cross Hospital LMU Munich, Munich, Germany.ORCID 0000-0001-5622-348X
Christian G StiefDepartment of Urology, University Hospital LMU Munich, Munich, Germany.
Michael ChaloupkaDepartment of Urology, University Hospital LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to assess the current trends and outcomes of retroperitoneal lymph node dissection (RPLND) in patients with testicular cancer in Germany, as well as to provide evidence on the role of the type of surgical approach, prior chemotherapy, and annual hospital caseload. We used the GeRmAn Nationwide inpatient Data, provided by the Research Data Center of the Federal Bureau of Statistics (2005-2022). We assessed trends and perioperative outcomes (mortality, intensive care unit [ICU] admission, transfusion, acute embolism, and length of hospital stay) based on the surgical approach (robotic, laparoscopic, and open), prior chemotherapy, and annual hospital caseload (with cut-offs of three and 10 cases/year) with a multivariable regression analysis. Overall, 6673 patients underwent RPLND for testicular cancer. Of them, 5570 (83%) received open, 819 (12%) laparoscopic, and 284 (5%) robot-assisted surgery. Patients had previously received chemotherapy in 1908 (29%) cases. Accordingly, 4431 (66%) patients underwent surgery in centers performing more than 3 cases/year, and 1325 (20%) in centers performing more than 10 cases/year. Over the past 18 years, the number of patients undergoing RPLND has decreased by half. In the multivariate regression analysis, a robotic and a laparoscopic approach was associated with lower odds of ICU admission, transfusion, and shorter hospital stay (p < .001) compared to an open approach. Patients undergoing surgery after prior chemotherapy presented similar perioperative outcomes compared to those who had not previously received chemotherapy. Similarly, patients undergoing surgery at high-volume centers presented comparable perioperative outcomes to those in low-volume centers based on the cut-off of three and 10 cases/year. Still, our findings were mitigated by selection bias. Overall, the number of annual RPLND cases in Germany has decreased over time.

Indexed as

Lymph Node ExcisionTesticular NeoplasmsAdultAgedBlood TransfusionGermanyHumansIntensive Care UnitsLaparoscopyLength of StayMaleMiddle AgedRetroperitoneal SpaceRobotic Surgical ProceduresTreatment OutcomeYoung Adultmortalityperioperative outcomesretroperitoneal lymph node dissectionrobotic RPLNDtesticular cancer

Identifiers

PMID40464407
PMCPMC12334906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.